Ketosis and cancer
Its potential as an adjunctive therapy
There is good evidence for the benefit of a ketogenic diet in type 2 diabetes, cardiovascular disease and epilepsy. There is emerging evidence in other neurological disorders (including Alzheimer’s disease) and cancer.
I will look at perhaps one of the least expected — cancer. To understand how ketones might help with such a devastating condition, it is necessary to look a bit closer at how cells in the body generate energy.
Our main dietary fuels are glucose (from carbohydrates), fatty acids (from fats) and amino aids (from proteins). There is no dietary source for ketones. Instead, the liver manufactures them when the body has adapted to fat-burning for energy (as with a ketogenic diet). The liver can also manufacture glucose, called gluconeogenesis, or release glucose from glycogen stores.
The ‘power generators’ of the cell that utilise these fuels are specialised compartments called mitochondria, which ‘burn’ fuel with oxygen (oxidation) to generate energy and release carbon dioxide and water. The main waste products are free radicals (reactive oxygen species) that the cell neutralises with antioxidants.
The mitochondria more or less directly burn fatty acids, ketones and amino acids. However, they cannot directly burn glucose. This requires a preliminary step, performed inside the cell but outside the mitochondria, where glucose is fermented anaerobically to produce pyruvate (a simple 3-carbon molecule). The mitochondria burn the pyruvate. Fermentation produces a little energy, but the mitochondria produce about 20 times more. It is this fermentation step, unique to glucose, that goes wrong in cancer cells.
Current thinking is that cancers arise from accumulating mutations that occur over time (perhaps decades) in a cell’s DNA that ultimately lead to damage to cell-growth genes and out of control growth and metastasis. This is the chromosomal hypothesis, because it was first recognised from chromosomal damage in cancer cells.
However, there is another model. In 1924, the German scientist Otto Warburg (1883–1970) showed that, despite great diversity in cancer types, cancer cells had one thing in common — hyperactive glucose metabolism. For this, he was awarded the Nobel prize (in 1931). This is the metabolic hypothesis, in which DNA damage is secondary to glucose hyper-metabolism. Conversely, the chromosomal model accepts that glucose metabolism is abnormal in cancer, but attributes it to a secondary effect from DNA damage.
While there does not seem to be agreement on cause-effect, there is agreement that most cancer cells have a much-increased need for glucose metabolism. Indeed, a gold-standard imaging method for identifying cancer in humans (PET scanning), works by imaging glucose metabolism.
What is happening to glucose inside a cancer cell?
It is fuelling the cell abnormally (the Warburg effect). The fermentation step (glucose to pyruvate) takes over from the mitochondria step (oxidation) as the main source of energy. Cancer cells have high energy needs, however fermentation is not very efficient at generating energy. As a result, the fermentation step gets massively up-regulated (by as much as 200-fold) to meet energy demand. Fermentation is a ‘dirty’ reaction, in that it produces large numbers of damaging free radicals as byproducts. The cancer cell uses these free radicals as weapons. It releases them into surrounding (healthy) tissue, where the free radicals damage and kill healthy cells (the Reverse Warburg Effect). Cancer cells consume the molecular debris released by the death of these healthy cells in order to grow and divide. In this way the cancer consumes, spreads and metastasises. Cancer cells take energy from glucose, and building blocks for growth by killing surrounding cells with the toxic waste.
However, the Achilles’ heel for cancer cells is that they need glucose to survive. Without it they may die. Cancer cells cannot derive energy from any other source — fatty acids, ketones or amino acids. Neither can they adapt to do so. Cancer cells are glucose dependent. That is why a low-carbohydrate ketogenic diet is relevant to cancer.
There is one other glucose-related mechanism relevant to cancer — insulin. Insulin does more than manage blood glucose and fat storage, it is also a regulator of cell growth. It does this indirectly through a class of molecules called insulin-like growth factors (IGFs). The combination of high blood glucose and high insulin levels as a result of a high-carbohydrate diet (particularly in insulin resistant individuals) may explain why diabetics have a higher incidence of cancer than the rest of the population.
A ketogenic diet and cancer
It should be obvious by now. By switching from glucose to ketones and fatty acids as fuel, restricting the availability of glucose and suppressing insulin, it seems reasonable to expect that cancer cells might suffer under a ketogenic diet.
There is now convincing evidence for this from laboratory studies (see here for a review). However, there have been no large-scale human studies to date (although they are in the pipeline). In the meantime, case-report studies in human cancer patients have shown that a ketogenic diet in late-stage cancer is safe to administer and can have remarkable results for some people. The diet is usually a calorie restricted ketogenic diet with very low carbohydrates that needs to be managed under medical supervision.
There will always be some circulating glucose with a ketogenic diet, no matter how severe it is, because the liver can manufacture glucose from fat (the glycerol in triglycerides) and protein (9 of the amino acids are glucogenic). It has been suggested that some diabetic medications, such as metformin, could be used to block this. There is evidence that metformin offers protection against some types of cancers (eg, breast cancer) and prolongs the life of diabetic patients with cancer.
Is a nutritional ketogenic diet likely to be protective against cancer in healthy individuals? This is not known, however the same reasoning applies — without regular glucose spikes and excess dietary glucose from carbohydrates, cancer cells may struggle to get established. Clinical trials are required.
I have provided the scientific rationale behind a (perhaps unexpected) role for a ketonic diet in cancer — it may not matter greatly what has caused a cancer to develop, if the cancer cells depend on glucose for energy then they could struggle.
However, it remains to be determined whether such a diet will prove to be a useful addition to current cancer treatments. We do not yet have the data.
Likewise, and for the same reasons, a ketogenic diet may confer a protective benefit against cancer in healthy individuals. Again, although plausible, this too is unproven.
Finally, the USDA high-carbohydrate low-fat diet has co-existed with a significant rise in the incidence of cancers, including childhood cancers, over the last 40 years or so. While this association does not prove causality, the level of glucose consumption on a high-carbohydrate diet is something to ponder, given that glucose metabolism is intimately involved in cancer.